Biohaven Pharmaceutical Total Stockholder Equity Over Time
| BHVN Stock | USD 29.86 0.54 1.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biohaven Pharmaceutical Performance and Biohaven Pharmaceutical Correlation. Biohaven |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Biohaven Pharmaceutical and related stocks such as Immunome, Inhibrx, and AGE Old Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMNM | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (35.6 M) | 41.3 M | 48.2 M | 16.7 M | 119.9 M | 137.9 M | 144.8 M |
| INBX | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (57.6 M) | (93.6 M) | 75.5 M | 52.4 M | 58.1 M | 43.5 M | 50 M | 52.5 M |
| DAWN | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (54.2 M) | (127.5 M) | (269.7 M) | 346.5 M | 502.8 M | 527.9 M |
| TERN | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 4.2 M | 68.6 M | 160.3 M | 276.9 M | 255.4 M | 293.7 M | 153.6 M |
| XFOR | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (56.6 M) | 58.7 M | 21.6 M | 129.2 M | 72.8 M | 64.4 M | 74.1 M | 51.1 M | 58.8 M | 46.6 M |
| INZY | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (33.2 M) | 158.1 M | 109.3 M | 118.6 M | 140.5 M | 161.6 M | 87.9 M |
| MREO | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 79.3 M | 62.5 M | 32.8 M | 40.3 M | (15 M) | 88 M | 61.9 M | 50.5 M | 45.5 M | 44.6 M |
| APLS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 13.2 M | 35 M | 23.8 M | 148.9 M | 161 M | 34.2 M | 204.6 M | 198.7 M | 169.9 M | 194.5 M | 228.5 M | 129.9 M |
| BPMC | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | 35.4 M | 144 M | 213.1 M | 624 M | 419 M | 464.4 M | 1.5 B | 970.7 M | 514.7 M | 130.6 M | 298.7 M | 484.3 M |
| KYMR | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (74.4 M) | 283.9 M | 459.6 M | 490.2 M | 395 M | 835.6 M | 877.4 M |
| RVMD | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 96.7 M | 152.5 M | 474.7 M | 602.6 M | 685.2 M | 1.8 B | 2.3 B | 2.4 B |
| CCCC | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (112 M) | 280.8 M | 389.6 M | 289.2 M | 246.1 M | 216 M | 193.3 M |
| AGIO | 63.1 M | 63.1 M | 43.9 M | 131.5 M | 424.4 M | 345.1 M | 358.6 M | 375.5 M | 687.5 M | 640.5 M | 399.5 M | 1.3 B | 1.1 B | 811 M | 1.5 B | 1.6 B |
| NRIX | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (57.7 M) | 290.3 M | 342.3 M | 303.7 M | 200.5 M | 527 M | 606 M | 636.3 M |
Biohaven Pharmaceutical and related stocks such as Immunome, Inhibrx, and AGE Old Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Biohaven Pharmaceutical Holding | BHVN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Connecticut; U.S.A |
| Exchange | New York Stock Exchange |
USD 28.4
Check out Biohaven Pharmaceutical Performance and Biohaven Pharmaceutical Correlation. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Biohaven Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.